<DOC>
	<DOCNO>NCT00833053</DOCNO>
	<brief_summary>Participants ongoing observational study ( P05319 ) limit ( adequate less optimal ) response infliximab randomize either increase frequency infliximab infusion every 8 week every 6 week , add weekly methotrexate current treatment plan . While receive infliximab study treatment ( ) , patient study attend regularly schedule office visit various clinical test safety effectiveness evaluation .</brief_summary>
	<brief_title>Dose Optimization Infliximab Moderate Severe Plaque Psoriasis ( Study P05315 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects must diagnosis moderate severe plaquetype psoriasis participate Study P05319 . Subjects must demonstrate adequate suboptimal response infliximab Study P05319 Subjects must least 18 year old Subjects must candidate phototherapy systemic treatment psoriasis . Subjects must pregnant must meet contraceptive requirement Subjects must meet tuberculosis screen criterion Subjects must meet laboratory medical history screening requirement Subjects infliximab methotrexate contraindicate recommended . Subjects already use certain investigational , biological , immunosuppressive drug Subjects certain comorbid condition Subjects currently history certain infection Subjects recently receive live virus bacterial vaccination Subjects situation condition , opinion investigator , may interfere optimal participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>